Travere Therapeutics, Inc. (TVTX)
Travere Therapeutics, Inc. (TVTX) is a healthcare company (biotechnology) based in the United States. The share price is $50.35, up 1.31% on the day, which values the company at $4.83B. Price as of 17 Nov 2026, 17:41 UTC, from Yahoo Finance.
Key facts
- Share price
- $50.35+1.31% today
- Market value
- $4.83B
- Forward P/E
- 9.3×
- Funk Score
- 40/100
- Against its own history
- Well above its usual priceusual price $19.23
- 200-week average
- $22.93120% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Travere Therapeutics, Inc. in more detail
TVTX trades at 9.3× next year's expected earnings, 7.4× sales. Measured against its own history, the price is 162% above what its usual multiples would imply ($19.23) — well above its usual price. It sits 120% above its 200-week average of $22.93.
Over the last five fiscal years Travere Therapeutics, Inc. has compounded revenue 19.9% a year. Its Funk Score is 40 out of 100 (financial strength 5.5, profitability 2.0, growth 8.6, value 0.0, each out of 10).
In its favour: Altman Z in the safe zone; Strong Piotroski score. Worth checking: Beneish M-score flags the accounts; Share count keeps rising.
1 of the superinvestors tracked here hold TVTX, including Polen Capital team (0.0% of the portfolio).
Superinvestors holding TVTX
1 of the investors tracked here report a position in their latest 13F filing.
- Polen Capital team Polen Capital Management0.03% of portfolio · $3.1M · added · Q3 2026
Health Care companies of similar size
- Merit Medical SystemsMMSI
- Edgewise TherapeuticsEWTX
- LivaNovaLIVN
- Ionis PharmaceuticalsIONS
- Dianthus TherapeuticsDNTH
- MiniMed GroupMMED
- Adaptive BiotechnologiesADPT
- HeartflowHTFL
- CRISPR TherapeuticsCRSP
- Option Care HealthOPCH
- Legend BiotechLEGN
- Definium TherapeuticsDFTX
Side by side:TVTX vs CRSP (Travere Therapeutics, Inc. vs CRISPR Therapeutics)TVTX vs HTFL (Travere Therapeutics, Inc. vs Heartflow)TVTX vs ADPT (Travere Therapeutics, Inc. vs Adaptive Biotechnologies)TVTX vs OPCH (Travere Therapeutics, Inc. vs Option Care Health)TVTX vs MMED (Travere Therapeutics, Inc. vs MiniMed Group)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Travere Therapeutics, Inc. (TVTX): questions and answers
What is Travere Therapeutics, Inc.'s market cap?
Travere Therapeutics, Inc. is valued at $4.83B at a share price of $50.35.
Is TVTX overvalued or undervalued?
Against its own history, TVTX is well above its usual price: the price is 162% above the $19.23 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is TVTX above its 200-week moving average?
Yes. TVTX is 119.6% above its 200-week average of $22.93. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Travere Therapeutics, Inc. growing?
Over the last five fiscal years Travere Therapeutics, Inc.'s revenue grew 19.9% a year; over ten years revenue grew 17.3% a year.
Does TVTX pay a dividend?
Travere Therapeutics, Inc. does not currently pay a regular dividend.
Which famous investors own TVTX?
In their latest quarterly filings, Polen Capital team (0.0% of the portfolio) hold TVTX. These filings are published up to 45 days after each quarter ends, so positions may have changed since.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Travere Therapeutics, Inc. (TVTX) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/TVTX
Underlying data: Yahoo Finance; company filings with the SEC.